- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Personalized Medicine: It May be High Cost, but It's Higher Value
Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever — and the ROI is gonna be big, both in patient outcomes and dollars saved.
Personalized medicine will be expensive in these early days of pioneering and planning. But individual genomic testing is not going to be exorbitant forever — and the ROI is gonna be big, both in patient outcomes and dollars saved, said a panel of speakers at MedCity’s CONVERGE conference in Philadelphia.
“Because pharmacogenomics is rooted in the pathobiology of disease, the implications of that are going to be huge moving forward,” said Hakon Hakonarson, director of the Center for Applied Genomics, The Children’s Hospital of Philadelphia. “But in the short term it’s going to be more expensive.”
To bridge the gap between today and a future where personalized medicine is the norm, companies are reaching for the low-hanging fruit: Cancer.
Read the full story here: http://bit.ly/UdU3Rd
Source: Med City News
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
